You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention
SBC: Pro-Change Behavior Systems, Inc. Topic: NIAAADESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Computerized Stage-Matched Intervention for Juvenile Offenders
SBC: Pro-Change Behavior Systems, Inc. Topic: NIDADESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
SBC: EPIVAX, INC. Topic: NIDDKDESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Novel antithrombotic agents to prevent hemodialysis vascular access failure
SBC: EVAS THERAPEUTICS LLC Topic: NHLBIDESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF creation and 77% at 1 year after AVG construction. Surgical trauma, repeated needle punctures, mechani ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Adjunctive Use of Apyrase to Fibrinolytic Therapy
SBC: APT THERAPEUTICS, INC. Topic: NHLBIDESCRIPTION (provided by applicant): Acute myocardial infarction is the leading cause of death in most industrialized nations. The estimated annual incidence in the US is 865,000 events, with ST-segment elevation myocardial infarction (STEMI, severe AMI)comprising an estimated 500,000 events per year. Fibrinolytic therapy is widely utilized to restore coronary blood flow due to its widespread ava ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Improved long-term biocompatibility of coronary stents by plasma coating process
SBC: NANOVA INC. Topic: NHLBIDESCRIPTION (provided by applicant): Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of cardiac disease due to their better ability to control restenosis than bare metal stents (BMS). However, a serious adverse outcome of late stent thrombosis in patients treated with DES has been reported, ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Treatment of Transplant Reperfusion with CD47 antibody
SBC: VASCULOX, INC. Topic: NHLBIDESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgical technique, organ preservation and immunosuppression, IRI remains a serious limitation and is responsible for delayed graft function, initial graft failure and contribtes to poor long-term graft surv ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Enhancing Biosynthesis of Biofuels from Cellulosic Biomass
SBC: COMPACT MEMBRANE SYSTEMS, INC. Topic: 88There continues to be a need for production of biofuels from agricultural sources. Butanol is a more attractive fuel than ethanol because it leads to better gas mileage, it achieves higher blends with gasoline than bioethanol, it has greater compatibility with existing fuel infrastructure, it is less volatile, it is more amenable to transport via pipeline due to low water absorption, there is no n ...
SBIR Phase II 2012 Department of Agriculture -
Thin Diamond for Time-of-Flight Detectors
SBC: Applied Diamond, Inc. Topic: 35bDetectors and radiation monitors for future high energy and nuclear physics experiments must be able to withstand radiation environments several orders of magnitude harsher than those of any current device. At present, most radiation detectors are based on silicon technology, however, the practical radiation hardness limit of silicon falls far short of requirements in future high ener ...
SBIR Phase I 2012 Department of Energy -
Novel Membrane Systems for Olefin/Paraffin Separation
SBC: COMPACT MEMBRANE SYSTEMS, INC. Topic: 18aEthylene and propylene are the primary feedstocks for the manufacture of polyethylene and polypropylene, respectively. These olefins represent a major component of the polymer manufacturing cost. Consequently, there is significant economic benefit in minimizing losses of unreacted olefin from the process. Some olefin loss is a result of the need to remove paraffin from the polymerization reactor ...
SBIR Phase I 2012 Department of Energy